SOLIGENIX INC. reached an agreement with FDA on the design of a phase III clinical trial evaluating SGX301 (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe